These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Wright RS; Collins MG; Stoekenbroek RM; Robson R; Wijngaard PLJ; Landmesser U; Leiter LA; Kastelein JJP; Ray KK; Kallend D Mayo Clin Proc; 2020 Jan; 95(1):77-89. PubMed ID: 31630870 [TBL] [Abstract][Full Text] [Related]
3. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. Ray KK; Wright RS; Kallend D; Koenig W; Leiter LA; Raal FJ; Bisch JA; Richardson T; Jaros M; Wijngaard PLJ; Kastelein JJP; N Engl J Med; 2020 Apr; 382(16):1507-1519. PubMed ID: 32187462 [TBL] [Abstract][Full Text] [Related]
4. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1. Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484 [TBL] [Abstract][Full Text] [Related]
5. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. Leiter LA; Teoh H; Kallend D; Wright RS; Landmesser U; Wijngaard PLJ; Kastelein JJP; Ray KK Diabetes Care; 2019 Jan; 42(1):173-176. PubMed ID: 30487231 [TBL] [Abstract][Full Text] [Related]
6. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. Ray KK; Landmesser U; Leiter LA; Kallend D; Dufour R; Karakas M; Hall T; Troquay RP; Turner T; Visseren FL; Wijngaard P; Wright RS; Kastelein JJ N Engl J Med; 2017 Apr; 376(15):1430-1440. PubMed ID: 28306389 [TBL] [Abstract][Full Text] [Related]
7. Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9. German CA; Shapiro MD BioDrugs; 2020 Feb; 34(1):1-9. PubMed ID: 31782112 [TBL] [Abstract][Full Text] [Related]
8. Inclisiran: A Game Changer in a Changing Game? Nambi V; Agha A J Am Coll Cardiol; 2021 Mar; 77(9):1194-1196. PubMed ID: 33663736 [No Abstract] [Full Text] [Related]
10. Renal Impairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran. Zijlstra LE; Trompet S; Mooijaart SP; van Buren M; Jukema JW Mayo Clin Proc; 2020 Jan; 95(1):12-14. PubMed ID: 31902406 [No Abstract] [Full Text] [Related]
11. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype? Hadjiphilippou S; Ray KK Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304 [TBL] [Abstract][Full Text] [Related]
12. Inclisiran for the treatment of dyslipidemia. Nishikido T; Ray KK Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410 [TBL] [Abstract][Full Text] [Related]
13. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran). Sinning D; Landmesser U Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390 [TBL] [Abstract][Full Text] [Related]
14. New hope for hyperlipidemia management: Inclisiran. Bandyopadhyay D; Hajra A; Ashish K; Qureshi A; Ball S J Cardiol; 2018 May; 71(5):523-524. PubMed ID: 29174841 [No Abstract] [Full Text] [Related]